Aimmune Expects ‘Robust’ Demand For Peanut Allergy Treatment Palforzia, Though Slow Launch
The COVID-19 Pandemic Is Expected To Affect The Launch
Aimmune CEO Jayson Dallas talked to Scrip about the company's field team, allergists' and payers' responses to the first food-derived medicine, and why Viaskin Peanut patch is not a competitive threat.
